11 results about "Renal vessels" patented technology

Method for determining the position of windows in aortic endoprostheses, using images from preoperative CT computed tomography, wherein such endoprosthesis comprises a tubular sleeve (1) having a diameter slightly greater than the diameter of such aorta, on which one or more windows (2) must be made in correspondence with the centre of origin of a blood vessel branching from such aorta. The method comprises the following steps: a) on the axial image of such tomography, calculating the aortic arc of circle (AA) between the position (PB) of such centre of origin of the vessel with respect to a reference point (OA) taken on the circumference of the aorta, b) calculating a conversion parameter (P) dependent on the difference between the diameter of the aortic artery and that of the tubular sleeve (1), c) determining the position of the window (PF) on the prosthesis by calculating the arc of circle on the prosthesis (AM) between a reference point (OM) taken on the tubular sleeve (1), placed in juxtaposition to such reference point (OA) on the aorta (A), and such position (PF), by subtracting the value of such conversion parameter (P) from the value of the aortic arc of circle (AA).

Provided herein are methods, devices, compositions, and kits for monitoring neuromodulation efficacy based on changes in the level or activity of one or more target biomarkers. A method can include transluminally delivering a distal portion of an elongated shaft of a catheter to a target renal blood vessel and at least partially inhibiting sympathetic neural activity of a renal nerve. The method includes determining a post-neuromodulation level of one or more biomarkers after at least partially inhibiting the sympathetic neural activity of the renal nerve, wherein the level of the one or more biomarkers directly or indirectly correlates with sympathetic nervous activity in the patient. The method can include comparing the post-neuromodulation level to a predetermined level for the one or more biomarkers, wherein the renal neuromodulation procedure is classified as at least partially successful if the post-neuromodulation level differs from the predetermined level.

A method for evaluating an outcome of renal denervation includes: acquiring first blood flow data from a first region in a renal blood vessel after a vasodilator injected into the first region is activated in a second region in the renal blood vessel; and acquiring second blood flow data from the first region after renal denervation is performed with a catheter for denervation.

A method of performing a therapeutic procedure includes navigating a therapeutic device to a location adjacent to target tissue, determining a first flow parameter within a blood vessel adjacent to the target tissue, applying neurostimulation to the target tissue and obtaining first images of blood vessels distal of the target tissue, applying therapy to the target tissue, applying neurostimulation to the target tissue, determining a second flow parameter within the blood vessel adjacent to the target tissue, comparing the second flow parameter to a flow parameter criteria, applying neurostimulation to the target tissue and obtaining second images of the blood vessels distal of the target tissue, comparing the first images to the second images to determine a vasoconstriction metric, and applying therapy to the target tissue if it is determined that the vasoconstriction metric satisfies a vasoconstriction criteria.

The present application belongs to the field of biomedical technology, and relates to a construction method of an experimental animal model and a constructed experimental model, in particular to a method for constructing a kidney humanized mouse model based on human cells and a constructed kidney humanized mouse model. The construction method comprises the following steps: injecting mesenchymal stem cells, human umbilical vein endothelial cells and human renal tubular epithelial cells separated from urine into immunodeficient mice subcutaneously or subcapsularly to obtain a humanized kidney vascular unit mouse model communicating with the host. The model construction has the following characteristics: the cells used are derived from urine, have the characteristics of sufficient clinical source and convenient sampling, and the kidney source cells derived from urine can represent a unique individual alone, can be used to establish an individualized kidney humanized mouse model based on patients, and have the potential to be applied to individualized precision medical research; the model can form a functional human kidney vascular unit in mice, and has great application prospects in individualized precision medical treatment of kidney disease and human kidney specific virus infection research.

The present invention belongs to the field of biomedical technologies, and particularly relates to the application of cinobufotalin in the preparation of drugs for treating tuberous sclerosis complex-related renal angiomyolipoma. The cinobufotalin can directly inhibit the growth of tuberous sclerosis complex-related renal angiomyolipoma cells and increase the protein expression level of apoptosis markers in tuberous sclerosis complex-related renal angiomyolipoma cells. The cinobufotalin can be used to prepare drugs for treating tuberous sclerosis complex-related renal angiomyolipoma. At the same time, the cost of cinobufotalin is relatively low, providing a new effective and low-cost potential drug for the treatment of tuberous sclerosis complex-related renal angiomyolipoma.

Systems and methods for performing and assessing neuromodulation therapy are disclosed herein. One method for assessing the efficacy of neuromodulation therapy includes positioning a neuromodulation catheter at a target site within a renal blood vessel of a human patient and delivering neuromodulation energy at the target site with the neuromodulation catheter. The method can further include obtaining a measurement related to a blood flow rate through the renal blood vessel via the neuromodulation catheter. The measurement can be compared to a baseline measurement related to the blood flow rate through the renal blood vessel to assess the efficacy of the neuromodulation therapy. In some embodiments, the baseline and post-neuromodulation measurements are obtained by injecting an indicator fluid into the renal blood vessel upstream of the target site and detecting a transient change in vessel impedance caused by the indicator fluid.

The invention provides application of AS-605240 in treatment of renal vascular smooth muscle lipoma related to nodular sclerosis, and belongs to the technical field of biological medicine. According to the application disclosed by the invention, the AS-605240 can be used for directly inhibiting the cell growth of the renal vascular smooth muscle lipoma related to the nodular sclerosis, and the AS-605240 can be used for preparing a medicine for resisting the renal vascular smooth muscle lipoma related to the nodular sclerosis, so that a new potential medicine is provided for treating the renal vascular smooth muscle lipoma related to the nodular sclerosis. The invention proves that AS-605240 can promote apoptosis of renal vascular smooth muscle lipoma cells related to the nodular sclerosis through a non-mTOR target point PI3K / AKT, so that the AS-605240 can treat the renal vascular smooth muscle lipoma related to the nodular sclerosis, and has good treatment and improvement effects on the renal vascular smooth muscle lipoma related to the nodular sclerosis.

The present invention belongs to the field of biomedicine technology and specifically relates to the use of artemisinin compounds in the preparation of drugs for treating tuberous sclerosis complex-associated renal angiomyolipoma. The artemisinin compounds can inhibit the growth of tuberous sclerosis complex-associated renal angiomyolipoma cells and have therapeutic efficacy in treating tuberous sclerosis complex-associated renal angiomyolipoma. Furthermore, artemisinin compounds are relatively abundant in source and relatively low in cost. Artemisinin compounds can be used to prepare drugs for treating tuberous sclerosis complex-associated renal angiomyolipoma, providing a new potential drug for the treatment of tuberous sclerosis complex-associated renal angiomyolipoma.

Disclosed herein is a method for treating renal disease in a subject that involves treating the subject with an effective amount of a compound of the formula (I). The disclosed method can in some embodiments, be used to treat any renal disease involving mitochondrial dysfunction. For example, in some embodiments, the renal disease involves acute kidney injury. As another example, in some embodiments, the renal disease involves diabetic kidney disease. In some embodiments, the renal disease is a glomerular disease (e.g. focal segmental glomerular sclerosis). In some embodiments, the renal disease is a renal vascular disease.

Systems and methods for performing and assessing neuromodulation therapy are disclosed herein. One method for assessing the efficacy of neuromodulation therapy includes positioning a neuromodulation catheter at a target site within a renal blood vessel of a human patient and delivering neuromodulation energy at the target site with the neuromodulation catheter. The method can further include obtaining a measurement related to a dimension of the renal blood vessel via a sensing element of the neuromodulation catheter. The measurement can be compared to a baseline measurement related to the dimension of the renal blood vessel to assess the efficacy of the neuromodulation therapy. In some embodiments, the baseline measurement is obtained via the sensing element of the neuromodulation catheter prior to delivering the neuromodulation energy.